Tamoxifen inhibits arterial accumulation of LDL degradation products and progression of coronary artery atherosclerosis in monkeys

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 17, Issue 2, 1997, Pages 403-408

  Williams, J Koudy ^a   Wagner, Janice D ^a   Li, Zhang ^a   Golden, Deborah L ^a   Adams, Michael R ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

atherosclerosis; cynomolgus monkey; females; LDL cholesterol; lipids; tamoxifen

Indexed keywords

ESTROGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TAMOXIFEN CITRATE; TRIACYLGLYCEROL;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG MECHANISM; FEMALE; HORMONAL REGULATION; LIPOPROTEIN METABOLISM; MACACA; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION;

EID: 0031029593     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.17.2.403     Document Type: Article

References (19)

1. Early Breast Cancer Triallists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet. 1992;339:1-15.
2. Bonadonna G, Valagussa P, Brambilla C, Moliterni A, Zambitti M, Ferrari LS. Adjuvant and neoadjuvant treatment of breast cancers with chemotherapy and endocrine therapy. Semin Oncol. 1991;18: 515-524.
3. Powles TJ. The case for clinical trials of tamoxifen for prevention of breast cancer. Lancet. 1992;340:1145-1147.
4. Fugh-Berman A, Epstein S. Tamoxifen: disease prevention or disease substitution? Lancet. 1992;340:1143-1145.
5. Neven P, De Muylder X, Van Belle Y, Vanderick G, De Muylder E. Hysteroscopic follow-up during tamoxifen treatment. Eur J Obstet Gynecol Reprod Biol. 1990;35:235-238.
6. Pornander T, Rutqvist IE, Sjoberg HE, Blomqvist L, Mattson A, Glas V. Long-term adjuvant tamoxifen in early breast cancer: effect on bone mineral density in postmenopausal women. J Clin Oncol. 1990;8:1019-1024.
7. McDonald CC, Stewart HJ, the Scottish Breast Cancer Committee. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. Br Med J. 1993;303:435-437.
8. Love RR, Mazess RB, Barden HS, Newcomb PA, Jordan VC. Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least two years. Breast Cancer Res Treat. 1988; 12:297-302.
9. Cuzick J, Wang DY, Bulbrook RD. The prevention of breast cancer. Lancet. 1986;l:83-86.
10. Dewer JA, Horobin JM, Preece PE, Tavendale R, Tunstall-Pedoe H, Wood RAB. Long term effects of tamoxifen on blood lipid values in breast cancer. Br Med J. 1992;305:225-226.
11. Bagdade JD, Woher J, Subbaiah PV, Ryan W. Effects of tamoxifen on plasma lipids and lipoprotein composition. J Clin Endocrinol Metab. 1990;70:1132-1135.
12. Ingram D. Tamoxifen use, estrogen binding and serum lipids in postmenopausal women with breast cancer. Austr N Z J Surg. 1990; 60:673-675.
13. Barren-Connor E, Bush TL. Estrogen and coronary heart disease in women. JAMA. 1991:265:1861-1867.
14. Adams MR, Williams JK, Kaplan JR. Effects of androgens on coronary artery atherosclerosis and atherosclerosis-related impairment of vascular responsiveness. Arterioscler Thromb Vase Biol. 1995; 15:562-570.
15. Allain CC, Poon LS, Chan CSG, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem. 1974;20: 470-475.
16. Fossati P, Principe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem. 1982;28:2077-2080.
17. Lipid Research Clinics Program. Manual of Laboratory Operations: Lipid and Lipoprotein Analysis. Bethesda, Md: National Institutes of Health; 1974. US Dept of Health, Education, and Welfare publication NIH 75-628.
18. Carroll RM, Rudel LL. Lipoprotein separation and low density lipoprotein molecular weight determination using high performance gel-filtration chromatography. J Lipid Res. 1983;24:200-207.
19. Auerbach BJ, Parks JS, Applebaum-Bowden D. A rapid and sensitive micro-assay for the enzymatic determination of plasma and lipoprotein cholasterol. J Lipid Res. 1990;31:738-742.